This Fortnight in Medicine XXV
From Sensible Medicine by Sensible Medicine Authors and Editors
May 6, 2026 · 30 min
About this episode
This episode discusses recent studies on the effectiveness of Nirmatrelvir–Ritonavir for COVID-19 and antihypertensive therapy post-intracerebral hemorrhage.
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients * Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage * Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe
Topics covered
- COVID-19 treatment
- hypertension therapy
- real-world effectiveness
- population-based study
- outpatient care
Keywords
- Nirmatrelvir
- Ritonavir
- COVID-19
- Taiwan
- hypertension
- antihypertensive agents
- real-world effectiveness
- outpatient care
Mentioned in this episode
Products: Nirmatrelvir–Ritonavir
Books & works: Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage, Effect of Combination Therapy on Adherence Among US Patients Initiating Therapy for Hypertension: a Cohort Study
Places: Taiwan
More episodes of Sensible Medicine
- This Fortnight in Medicine XXVII · June 3, 2026 · 33 min
- This Fortnight in Medicine XXVI · May 20, 2026 · 55 min
- This Fortnight in Medicine XXIV · April 22, 2026 · 46 min
- This Fortnight in Medicine XXIII · April 8, 2026 · 34 min
- This Fortnight in Medicine XXII · March 24, 2026 · 40 min
- This Fortnight in Medicine XXI · March 11, 2026 · 36 min
Explore listener stats, chart rankings, contacts and more on the Sensible Medicine podcast page.